Alzheimer’s Big Break: Donanemab Slows Progression by 35%
After decades of limited progress in Alzheimer’s treatment, 2024 brought groundbreaking news that has transformed hope into reality. The FDA officially approved donanemab (brand name Kisunla) in July 2024, marking only the second drug ever to receive traditional approval for actually changing the course of Alzheimer’s disease, not just masking symptoms. This remarkable breakthrough stems […]